The role of colchicine in the treatment of covid-19 patients

The role of colchicine in the treatment of covid-19 patients hospitalized in the intensive care unit

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210913052467N1

Enrollment

Registered

2022-04-29

Start date

2022-05-22

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Pneumonia due to SARS-associated coronavirus

Interventions

Intervention 1: Intervention group: Patients will recieve methylprednisolone, ramsadivir, cefipime, vitamin C, vitamin D, vitamin E, diphenhydramine and pantoprazole

the dose of which according to the ICU specialist with 1 mg loading and 0.5 mg of colchicine and 0.5 mg every morning and night for 10 days. Intervention 2: Control group: Patients will recieve methyl

the dose of which according to the ICU specialist for 10 days.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Proved Covid-19 diagnosis based on positive PCR test or clinical evidence and CT scan of the lung Hospitalized in the intensive care unit Satisfaction for the study

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Liver failure Patient dissatisfaction Sensitivity to colchicine Renal glomerular clearance less than 20

Design outcomes

Primary

Measure	Time frame
Disease severity. Timepoint: At the beginning of the study and 10 days after the intervention. Method of measurement: APACHE Score II.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactOmid Reshadi

Tabriz University of Medical Sciences

Dr.omidre@gmail.com+98 44 3625 8506

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026